What Happened

Capricor Therapeutics presented five-year data from its HOPE-2 Open-Label Extension study at the PPMD 2026 Annual Conference, showing Deramiocel's sustained efficacy in slowing DMD progression and stabilizing cardiac function. The results align with earlier Phase 3 trial data, supporting its FDA submission ahead of the August 2026 PDUFA date.

Who Is Affected

DMD patients, particularly non-ambulant boys, and their families stand to benefit from Deramiocel's potential approval. Treatment centers, neurologists, and cardiologists specializing in DMD are key stakeholders, as are payers evaluating coverage for a new therapy.

Market Impact

• FDA decision imminent: BLA under review with August 2026 PDUFA date.
• Limited competition: Deramiocel targets both skeletal and cardiac muscle deterioration, a dual benefit.
• Orphan drug status: Grants market exclusivity and pricing leverage.

What to Watch

Monitor FDA approval by August 2026 and Capricor's commercialization plans. Track adoption by DMD treatment centers and payer reimbursement decisions, which will dictate market access.